ObjectivesTo examine the utility and efficacy of a multifaceted protocol for the administration of intravesical bacillus Calmette–Guerin (BCG) for non‐muscle‐invasive bladder cancer (NMIBC).Subjects and methodsA multicenter retrospective review was conducted among 83 patients undergoing Fremantle protocol intravesical BCG for NMIBC within 4 major hospitals in Western Australia between January 2016 and December 2018. The Fremantle protocol consists of weekly BCG instillations for 6 weeks during the induction phase, followed by monthly BCG instillations for 10 months during the maintenance phase with integrated clearance‐to‐proceed algorithms for urine MSU checks, flexible cystoscopies performed at 3 monthly intervals during maintenance BCG, and repeat GA cystoscopies with four quadrant bladder biopsies routinely obtained following the completion of induction and maintenance treatment.ResultsFor patients undergoing Fremantle protocol BCG, 98.8% (82/83) and 75.9% (63/83) of patients completed their induction and maintenance courses of BCG, respectively. Induction BCG was delivered over a median duration of 35 days (range 34–84 days), and maintenance BCG was delivered over a median duration of 266 days (range 1–682 days). The tumor recurrence rate was 10.8% (9/83) at the time of post‐induction biopsies, 2.4% (2/83) during maintenance treatment, 0% (0/60) at the time of post‐maintenance biopsies, and 8.8% (5/57) after a median further follow‐up of 16 months (range 0–51 months).ConclusionThe Fremantle protocol appears to be a safe and effective BCG regimen with several advantages over other BCG protocols, including high completion rates, low recurrence rates, and being highly pragmatic.